Pfizer and biontech announce omicron-adapted covid-19 vaccine candidates demonstrate high immune response against omicron

New york and mainz, germany, june 25, 2022 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced positive data evaluating the safety, tolerability, and immunogenicity of two omicron-adapted covid-19 vaccine candidates: one monovalent and the other bivalent, a combination of the pfizer-biontech covid-19 vaccine and a vaccine candidate targeting the spike protein of the omicron ba.1 variant of concern. data from the phase 2/3 trial found that a booster dose of both omicron-adapted vaccine candidates elicited a substantially higher immune response against omicron ba.1 as compared to the companies' current covid-19 vaccine. the robust immune response was seen across two investigational dose levels, 30 Μg and 60 Μg.
BNTX Ratings Summary
BNTX Quant Ranking